| Name | Title | Contact Details |
|---|
PWNHealth is a national clinician network working to improve early detection and prevention of disease using advanced diagnostics and telehealth. Our model enables safe and easy access to diagnostic testing, ensuring clinical validity, utility, quality consumer education, access to clinicians, and the ability to implement national programs seamlessly. Our solutions provide the clinical, legal, and technological framework to facilitate population-scale testing across key healthcare markets. Through integration with more than 80 CLIA-certified labs and support of over 3,000 test types, we are shaping a new paradigm in healthcare, servicing all 50 states and Puerto Rico. We believe that empowering people with convenient access to clinically actionable testing has the power to change lives, improve outcomes, and create a healthier world. PWNHealth is backed by leading growth equity firms Spectrum Equity and the Blue Venture Fund (BVF).
Environmental Health is a Newton Center, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Motion Concepts Canada is a Concord, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.
Valley Aids Council is a Harlingen, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.